Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Depreciation and Depletion (2024 - 2026)

Cytosorbents posted quarterly Depreciation and Depletion of $289000.0 for Q1 2026, down 3.67% year-on-year from $300000.0 in Q1 2025, and down 3.67% on a QoQ basis from $300000.0 in Q4 2025.

Cytosorbents (CTSO) has 3 years of Depreciation and Depletion data on file, last reported at $289000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation and Depletion fell 3.67% year-over-year to $289000.0; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (down 12.43% YoY), and the FY2025 full-year result was $1.2 million, down 7.69% from the prior year.
  • Depreciation and Depletion for Q1 2026 stood at $289000.0, down from $300000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $457800.0 in Q2 2024 and bottomed at $289000.0 in Q1 2026.
  • The 3-year median for Depreciation and Depletion is $300000.0 (2024), against an average of $321000.0.
  • Peak annual rise in Depreciation and Depletion reached 0.0% in 2025, while the deepest fall reached 34.47% in 2025.
  • A 3-year view of Depreciation and Depletion shows it stood at $300000.0 in 2024, then changed by 0.0% to $300000.0 in 2025, then declined by 3.67% to $289000.0 in 2026.
  • The last three Depreciation and Depletion figures came in at $289000.0 (Q1 2026), $300000.0 (Q4 2025), and $300000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation and Depletion (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 381.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 120.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 308.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 29.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 78.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Cytosorbents 28.81 Mn 24.01 Mn 6.13 Mn 289,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 289,000.00
Mar 31, 2026 289,000.00
Dec 31, 2025 300,000.00
Dec 31, 2025 300,000.00
Sep 30, 2025 300,000.00
Sep 30, 2025 300,000.00
Jun 30, 2025 300,000.00
Jun 30, 2025 300,000.00
Mar 31, 2025 300,000.00
Mar 31, 2025 300,000.00
Dec 31, 2024 300,000.00
Dec 31, 2024 300,000.00
Sep 30, 2024 300,000.00
Sep 30, 2024 300,000.00
Jun 30, 2024 457,800.00
Jun 30, 2024 457,800.00
Mar 31, 2024 342,200.00
Mar 31, 2024 342,200.00